Timothy S Pardee (Timothy Pardee)

Years Active: 2017-2022
Publications (10 Years): 4

This page only lists publications with an associated author ORCID identifier.

Publications

Rebecca Anderson, Lance D Miller, Scott Isom, Jeff W Chou, Kristin M Pladna, Nathaniel J Schramm, Leslie R Ellis, Dianna S Howard, Rupali R Bhave, Megan Manuel, Sarah Dralle, Susan Lyerly, Bayard L Powell, Timothy S Pardee
Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia. Nature communications 13 (1) (2022)
Samuel J Yates, Susan Lyerly, Megan Manuel, Janet A Tooze, Heidi D Klepin, Bayard L Powell, Sarah Dralle, Alok Uprety, Timothy S Pardee
The prognostic value of standardized phase angle in adults with acute leukemia: A prospective study. Cancer medicine 9 (7) (2020)
Michael Heuser, Neil Palmisiano, Ioannis Mantzaris, Alice S Mims, Courtney D D DiNardo, Lewis R Silverman, Eunice S Wang, Walter Fiedler, Claudia Baldus, Sebastian Schwind, Timothy S Pardee, Alexander E Perl, Charles Cai, Stefan Kaulfuss, Eleni Lagkadinou, Christine Rentzsch, Markus Wagner, Gary Wilkinson, Bingyan Wu, Michael Jeffers, Isabelle Genvresse, Alwin Krämer
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. Leukemia 34 (11) (2020)
Peter M Alexander, David L Caudell, Gregory L Kucera, Kristin M Pladna, Timothy S Pardee
The novel phospholipid mimetic KPC34 is highly active against preclinical models of Philadelphia chromosome positive acute lymphoblastic leukemia. PloS one 12 (6) (2017)

Timothy S Pardee.css-eqlu8i{font-size:small;padding-left:4px;} (Timothy Pardee)